Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial

Xiaoyi Ning, Yun Kuang, Guoping Yang, Jinlian Xie, Da Miao, Chengxian Guo, Zhijun Huang, Xiaoyi Ning, Yun Kuang, Guoping Yang, Jinlian Xie, Da Miao, Chengxian Guo, Zhijun Huang

Abstract

This study aimed to analyze the influence of renal insufficiency on the anticoagulant effects and safety of warfarin in Chinese patients. Data on the creatinine levels of participants enrolled in a randomized controlled study were screened and divided into the non-renal insufficiency group, mild renal insufficiency group, and moderate renal insufficiency group, according to the creatinine clearance rate. The primary outcome measures were stable dose and average daily dose of warfarin. Secondary outcome measures were percentage of time in the therapeutic international normalized ratio (INR) (%TTR), and the first time to reach the therapeutic INR. Adverse events included bleeding events, thromboembolic events, and mortality. All participants with renal function test results and a baseline INR of less than 1.5 were included in the primary and secondary outcome analysis. The SPSS Statistics 21.0 software was used for statistical analysis. The randomized controlled trial was registered in Clinicaltrials.gov (NCT02211326). A total of 571 patients were included in this analysis. Multiple regression analysis showed that the renal function was correlated with stable dose, average daily dose, and the first time to reach therapeutic INR after adjusting for confounding factors. However, no correlation was noted between kidney function and %TTR. No significant differences were observed across the various safety parameters among the three groups. Renal function is an important consideration in patients using warfarin.

Keywords: Anticoagulants; Chronic kidney disease; Thromboembolism; Warfarin.

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. Albrecht D, Turakhia MP, Ries D, Marbury T, Smith W, Dillon D, Milner PG, Midei MG. Pharmacokinetics of tecarfarin and warfarin in patients with severe chronic kidney disease. Thromb Haemost. 2017;117:2026–2033. doi: 10.1160/TH16-08-0623.
    1. Altawalbeh SM, Alshogran OY, Smith KJ. Cost-utility analysis of apixaban versus warfarin in atrial fibrillation patients with chronic kidney disease. Value Health. 2018;21:1365–1372. doi: 10.1016/j.jval.2018.06.009.
    1. Bonde AN, Lip GYH, Kamper AL, Hansen PR, Lamberts M, Hommel K, Hansen ML, Gislason GH, Torp-Pedersen C, Olesen JB. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014;64:2471–2482. doi: 10.1016/j.jacc.2014.09.051.
    1. Canga Y, Guvenc TS, Calik AN, Karatas MB, Akdeniz E, Yuksel G, Emre A (2018) Renal function in patients with mechanical prosthetic valves : long-term effects of anticoagulation and over-anticoagulation with warfarin Wien Klin Wochenschr 130:436-445
    1. Carrero JJ, Evans M, Szummer K, Spaak J, Lindhagen L, Edfors R, Stenvinkel P, Jacobson SH, Jernberg T. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA. 2014;311:919–928. doi: 10.1001/jama.2014.1334.
    1. Chang SH et al. (2019) Efficacy and safety of oral anticoagulants in patients with atrial fibrillation and stages 4 or 5 chronic kidney disease Am J Med
    1. Connolly SJ, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029–2037. doi: 10.1161/CIRCULATIONAHA.107.750000.
    1. Dreisbach AW, Japa S, Gebrekal AB, Mowry SE, Lertora JJ, Kamath BL, Rettie AE. Cytochrome P4502C9 activity in end-stage renal disease. Clin Pharmacol Ther. 2003;73:475–477. doi: 10.1016/S0009-9236(03)00015-8.
    1. Guo C et al (2020) Genotype-guided dosing of warfarin in Chinese adults: a multicenter randomized clinical Trial. Circ Genom Precis Med. 10.1161/CIRCGEN.119.002602
    1. Hirai T, Hamada Y, Geka Y, Kuwana S, Hirai K, Ishibashi M, Fukaya Y, Kimura T. A retrospective study on the risk factors for bleeding events in warfarin therapy, focusing on renal function. Eur J Clin Pharmacol. 2017;73:1491–1497. doi: 10.1007/s00228-017-2316-1.
    1. Jun M, et al. Warfarin initiation, atrial fibrillation, and kidney function: comparative effectiveness and safety of warfarin in older adults with newly diagnosed atrial fibrillation. Am J Kidney Dis. 2017;69:734–743. doi: 10.1053/j.ajkd.2016.10.018.
    1. Kamali F. Genetic influences on the response to warfarin. Curr Opin Hematol. 2006;13:357–361. doi: 10.1097/01.moh.0000239708.70792.4f.
    1. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, Pirmohamed M, Caldwell MD, Limdi N, Burmester JK, Dowd MB, Angchaisuksiri P, Bass AR, Chen J, Eriksson N, Rane A, Lindh JD, Carlquist JF, Horne BD, Grice G, Milligan PE, Eby C, Shin J, Kim H, Kurnik D, Stein CM, McMillin G, Pendleton RC, Berg RL, Deloukas P, Gage BF. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther. 2010;87:572–578. doi: 10.1038/clpt.2010.13.
    1. Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, Acton RT, Allon M. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009;20:912–921. doi: 10.1681/ASN.2008070802.
    1. Limdi NA, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis. 2010;56:823–831. doi: 10.1053/j.ajkd.2010.05.023.
    1. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ, International Warfarin Pharmacogenetics Consortium Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010;115:3827–3834. doi: 10.1182/blood-2009-12-255992.
    1. Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, Zhu J, Jansky P, Sigamani A, Morillo CA, Liu L, Damasceno A, Grinvalds A, Nakamya J, Reilly PA, Keltai K, van Gelder I, Yusufali AH, Watanabe E, Wallentin L, Connolly SJ, Yusuf S, RE-LY Atrial Fibrillation Registry Investigators Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation. 2014;129:1568–1576. doi: 10.1161/CIRCULATIONAHA.113.005451.
    1. Olesen JB et al. (2012) Stroke and bleeding in atrial fibrillation with chronic kidney disease N Engl J Med 367:625-635
    1. Piccini JP, et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc. 2014;3:e000521. doi: 10.1161/JAHA.113.000521.
    1. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138:1093-1100
    1. Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat Rev Nephrol. 2018;14:337–351. doi: 10.1038/nrneph.2018.19.
    1. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236–239. doi: 10.1055/s-0038-1651587.
    1. Usrds 2017 Annual Data Report Volume 1: chronic kidney disease. Cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis. 2018;71:S77–S94. doi: 10.1053/j.ajkd.2018.01.007.
    1. Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127:2166–2176. doi: 10.1161/CIRCULATIONAHA.112.142158.
    1. Wallentin L, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975–983. doi: 10.1016/S0140-6736(10)61194-4.
    1. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007;167:1414–1419. doi: 10.1001/archinte.167.13.1414.
    1. Zhang L, et al. Oral anticoagulation for atrial fibrillation thromboembolism prophylaxis in the chronic kidney disease population: the state of the art in 2019. Cardiovasc Drugs Ther. 2019;33:481–488. doi: 10.1007/s10557-019-06885-x.
    1. Zhang L, et al. Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis. 2008;51:373–384. doi: 10.1053/j.ajkd.2007.11.009.
    1. Zhong SL, Yu XY, Liu Y, Xu D, Mai LP, Tan HH, Lin QX, Yang M, Lin SG. Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients. Pharmacogenet Genomics. 2012;22:176–182. doi: 10.1097/FPC.0b013e32834f45f9.
    1. Zhu J, Zhang W, Li Y, Zhang W, Wang H, Zheng W, Wang C. ARMS test for diagnosis of CYP2C9 and VKORC1 mutation in patients with pulmonary embolism in Han Chinese. Pharmacogenomics. 2010;11:113–119. doi: 10.2217/pgs.09.138.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe